Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy

TGF-β has been implicated as a major pathogenic factor in diabetic nephropathy. This randomized, double-blind, phase 2 study assessed whether modulating TGF-β1 activity with a TGF-β1–specific, humanized, neutralizing monoclonal antibody (TGF-β1 mAb) is safe and more effective than placebo in slowing...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Soc Nephrol
Autors principals: Voelker, James, Berg, Paul H., Sheetz, Matthew, Duffin, Kevin, Shen, Tong, Moser, Brian, Greene, Tom, Blumenthal, Samuel S., Rychlik, Ivan, Yagil, Yoram, Zaoui, Philippe, Lewis, Julia B.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2017
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5328150/
https://ncbi.nlm.nih.gov/pubmed/27647855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2015111230
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars